News & Updates

New drug applications approved by US FDA as of 15-30 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with fostamatinib, a spleen tyrosine kinase inhibitor that targets B cells and plasma cells, is well tolerated by patients with hidradenitis suppurativa (HS), resulting in improved clinical outcomes with no serious adverse events, a study has shown.

Chronic wounds impose a substantial economic burden on Singapore, costing the country approximately 0.07 percent of its gross domestic product (GDP) annually, as reported in a study.

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

Children and adults with atopic dermatitis (AD) are at risk of inflammatory bowel disease (IBD), with the risk varying by age, AD severity, and IBD subtype, according to a study.

Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis  (AD) as shown in an Asian retrospective cohort study.